ALMS — Alumis Inc. stock price, charts and financials

QT77Alumis Inc.

Alumis Inc. (NASDAQ: ALMS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
27.23
-0.37-1.32%
OverviewShort InterestFilings
ALMSQT77Alumis Inc.·NASDAQ
27.23-1.32%
Earnings
Down 1.3% — Earnings due 2026-08-12 — pre-report positioning.
Medium confidence
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TNGX+0.57%$27.23RLAY+2.22%$20.21IDYA-0.27%$36.92NAMS-0.16%$27.91MBX-2.74%$65.96RCUS-0.24%$28.55QURE-0.76%$46.07ARQT+1.46%$25.66
Snapshot
Index-P/E-EPS (ttm)-1.92Insider Own36.51%Shs Outstand123.43MPerf Week-2.30%
Market Cap3.41BForward P/E-EPS next Y-2.73Insider Trans-0.04%Shs Float85.84MPerf Month-8.91%
Enterprise Value3.38BPEG-EPS next Q-Inst Own-Short Float7.88%Perf Quarter16.16%
Income-234.38MP/S-EPS this Y-49.67%Inst Trans-Short Ratio4.99Perf Half Y4.78%
Sales8.40MP/B6.09EPS next Y4.86%ROA-35.35%Short Interest6.76MPerf YTD182.79%
Book/sh-P/C-EPS next 5Y-ROE-54.63%52W High30.93 -11.96%Perf Year531.58%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-71.89%52W Low3.71 634.04%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin89.63%Volatility5.57% 6.30%Perf 5Y-
Dividend TTM-EV/Sales-EPS Y/Y TTM62.24%Oper. Margin-5364.02%ATR (14)1.76Perf 10Y-
Dividend Ex-Date-Quick Ratio7.51Sales Y/Y TTM-Profit Margin-2825.70%RSI (14)51.65Recom2.13
Dividend Gr. 3/5Y-Current Ratio7.51EPS Q/Q59.34%SMA20-0.84%Beta1.32Target Price39.17
Payout0.00%Debt/Eq0.06Sales Q/Q-88.24%SMA508.31%Rel Volume0.60Prev Close27.60
Employees224LT Debt/Eq0.11EarningsAug 12SMA20034.41%Avg Volume1.30MPrice27.23
IPO DateJun 28, 2024Option/ShortYes / YesEPS/Sales Surpr.0.37% -15.41%Net Debt/EBITDA0.07Volume782,706Change-1.32%
Analyst Ratings
DateActionAnalystRatingTarget
May-19-26ReiteratedChardan CapitalBuy$37 → $40
May-15-26ReiteratedMorgan StanleyOverweight$38 → $39
May-15-26DowngradeHC Wainwright & Co.Buy → Neutral$40 → $25
May-15-26ReiteratedWells FargoOverweight$39 → $51
May-15-26ReiteratedGuggenheimBuy$32 → $34
Mar-10-26ReiteratedRaymond James$46
Jan-21-26InitiatedChardanBuy$37
Jan-21-26ReiteratedLoop Capital Markets$37
Jan-09-26ReiteratedHC Wainwright & Co.Buy$20 → $40
Jan-07-26ReiteratedMorgan StanleyOverweight$33
Latest News
Company

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue2400—
Cost of Goods Sold Incl. D&A330—
Gross Profit21-30—
Selling, General and Administrative Excl. Other923520—
Research and Development386266138—
Other Operating Expense-30-30—
Operating Income-427-301-158—
Interest Expense
000—
Unusual Expense
————
Non-Operating Income (Expense)17573—
Net Income Before Taxes-252-294-155—
Income Taxes-900—
Consolidated Net Income-243-294-155—
Net Income From Continuing Operations-243-294-155—
Net Income-243-294-155—
EPS (Recurring)-2.32-10.38-2.99—
EPS (Basic, Before Extraordinaries)-2.32-10.38-2.99—
EPS (Diluted)-2.32-10.38-2.99—
EBITDA-248-291-154—
Other After Tax Adjustments
————
Stock Option Compensation Expense
————
Price To Earnings Ratio
————
Price To Sales Ratio345.67———
Gross Margin87.50———
Operating Margin-1,779.17———
Net Margin-1,012.50———
Shares Outstanding8502852—
Market Capitalization8,296220——
Operating Lease Expense
————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$34.42$25.49$16.55$7.61$-1.33● Close Price0.00M7.75M15.50M23.25M31.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Goldstein David MChief Scientific OfficerAug 03 '26Sale26.372,59668,45730,970Aug 05
Hardiman Roy C.Chief Business & Strategy OfcrAug 03 '26Sale26.372,69270,988207,746Aug 05
Schroer John R.Chief Financial OfficerAug 03 '26Sale26.373,28286,54624,718Aug 05
Drappa JornChief Medical OfficerAug 03 '26Sale26.372,44764,52756,892Aug 05
Bradley Mark ChristopherChief Development OfficerAug 03 '26Sale26.372,57267,82448,533Aug 05
Pangali SanamChief Legal OfficerAug 03 '26Sale26.371,36435,9699,747Aug 05
Pangali SanamChief Legal OfficerJul 06 '26Sale28.005,000140,00011,111Jul 08
Pangali SanamChief Legal OfficerJul 06 '26Option Exercise5.065,00025,30016,111Jul 08
Drappa JornChief Medical OfficerMay 22 '26Option Exercise6.6526,852178,64959,339May 27
AKKARAJU SRINIVASDirectorJan 09 '26Buy17.00588,2359,999,9951,853,488Jan 13
Foresite Labs, LLC10% OwnerJan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12
Foresite Capital Management VI LLC10% OwnerJan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12
Tananbaum James B.director, 10 percent owner:Jan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12
AKKARAJU SRINIVASDirectorDec 05 '25Buy9.84186,3771,833,7601,265,253Dec 09
AKKARAJU SRINIVASDirectorDec 04 '25Buy8.1866,027540,1011,078,876Dec 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.